ScRNA-seq holds promise for improving our understanding of the molecular characteristics of cancer, and potentially contributing to improved diagnosis, prognosis, and therapeutics.Background Tumors are generally considered to be of monoclonal origin, with mutations facilitating the expansion of a malignant ...
In conclusion, the IASLC staging criteria for SCLC patients have a higher prognostic impact and are therefore preferable in clinical practice and future therapeutic trials. 展开 关键词: small cell lung cancer staging classification prognosis international association for the study of lung cancer veterans...
Although additional cytogenetic abnormalities (ACA) do not affect the prognosis of patients with t(15;17) acute promyelocytic leukemia (APL), the role of a... - 《Leukemia & Lymphoma》 被引量: 0发表: 2018年 Phase II trial of weekly dose-dense paclitaxel in extensive-stage small cell lung...
In addition to a worse prognosis due to the underlying malignancies, Group I AE are generally characterized by a worse treatment response and are more likely to induce irreversible tissue damage [1]. Such differences are related to the underpinning pathophysiological mechanisms. While in Group II ...
While most patients with SCLC respond initially to cytotoxic therapy, almost all tumours recur and are resistant to further therapy. The mortality is very high, resulting in SCLC being designated as a recalcitrant cancer. As tumours in patients with SCLC are seldom resected, tumour materials for ...
SCLC is extremely sensitive to standard therapies, including conventional cytotoxic chemotherapies and radiotherapy, but the prognosis is very poor with short survival. Despite several treatment attempts and new strategic approaches investigated, in the last decades, for the management of SCLC, only ...
Based on their mechanisms of action and available clinical data, immunotherapy agents may provide greatest clinical benefit if used as early as possible in the treatment paradigm when patients have a better prognosis. Furthermore, patients who eventually undergo disease progression after immunotherapy may...
Excessive production of these hormones or peptides may be associated with specific clinical syndromes and is a distinctive feature of NETs. Poorly differentiated neuroendocrine carcinomas (NECs) substantially differ from NETs in terms of biologic aggressiveness, response to treatments and prognosis [5,6...
(CREST-Calcinosis, Raynaud's phenomenon, oesophageal dysmotility, sclerodactyly, and telangectasia) with high prevalence of anti centromere antibody (ACA), and the diffuse systemic sclerosis (dSSc) which has high prevalence of anti topoisomerase antibodies I (anti-topo I), and worse prognosis (1)...
Due to the generally poor prognosis of head and neck squamous cell carcinoma (HNSCC), treatment has been intensified, these last decades, leading to an inc... H Mirghani,F Amen,P Blanchard,... - 《International Journal of Cancer》 被引量: 103发表: 2015年 Is the Blood–Brain Barrier Rel...